Jeffrey Martini
Chief Scientific OfficerDr. Jeffrey Martini, also known as Jeff, Ph.D. was Senior Vice President of R&D and Scientific Affairs of Palvella Therapeutics, Inc. from August 2020 to October 2024. Dr. Martini was previously the Chief Scientific Officer of Legacy Palvella from October 2024 to December 2024. Dr. Martini Martini is Chief Scientific Officer of Palvella Therapeutics, Inc. from December 2024. Prior to Palvella, he served as Executive Director of Business Development and Corporate Strategy at Marinus Pharmaceuticals. Previously. Dr. Martini was Project Champion at Teva Specialty Pharmaceuticals and Cephalon Pharmaceuticals where he led the cross functional development teams for several therapeutic areas and was responsible for program strategy and delivery. Prior experiences include research scientist roles at GSK and Centocor and as an investment consultant at Ben Franklin Technology Partners where he led the due diligence for early stage investments. Dr. Martini has experience leading programs at all stages of development, including IND submission through NDA approval and product launch. Dr. Martini holds a B.S. in Life Sciences from Penn State University and a PhD in Molecular Pharmacology and Structural Biology from Jefferson University.
Positions
- Company NamePalvella Therapeutics, Inc.Stock CodePVLAPositionChief Scientific OfficerColleagues
- WHWesley H. KaupinenFounder, President, CEO & Director
- GMGeorge M. JenkinsIndependent Chairman of the Board
- MEMatthew E. KorenbergCFO, Corporate Secretary & Treasurer
- KGKathleen GoinChief Operating Officer
- MBMarcy B. NanusVice President of Investor Relations & Corporate Affairs
- TCTodd C. DavisIndependent Director
- CPChristopher P. KiritsyIndependent Director
- EJElaine J. HeronIndependent Director
